Our latest news & events

TREEFROG THERAPEUTICS ENTERS INTO PIONEERING RESEARCH COLLABORATION IN IMMUNO-ONCOLOGY WITH THE UNIVERSITY OF PITTSBURGH

TreeFrog Therapeutics Picks-Up Best Poster Award At The International Society For Cell & Gene Therapy (ISCT) Annual Meeting For Their Cell Therapy Program In Parkinson’s Disease

TreeFrog Presents Data From Their Parkinson’s Disease Cell Therapy Program At The 29th World Congress On Parkinson’s Disease And Related Disorders (IAPRD) In Lisbon

Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes

TreeFrog Presents Data From Their Parkinson’s Cell Therapy Program At The American Academy Of Neurology Annual Meeting

TreeFrog’s Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

TreeFrog Therapeutics reinforces Executive Committee with three new members.

GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells.

The whole team wishes you a Merry Christmas & Happy New Year !

The machine will be transferred in 2023 to a contract development and manufacturing organization (CDMO) to produce TreeFrog’s cell therapy candidate for Parkinson’s disease, with the aim of a first-in-human trial in 2024. Over 2023, Invetech will deliver three additional GMP encapsulation devices to support TreeFrog’s in-house and partnered cell therapy programs in regenerative medicine and immuno-oncology.

TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs.

TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs.

TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), today announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs.

The whole team at TreeFrog Therapeutics wishes you a Happy New Year !

TreeFrog Therapeutics celebrated its 3rd anniversary on December 7th, 2021, announcing that the company increase its clean room capacity by two-fold in Pessac, to support its acceleration in cell therapy.

TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series B financing round, bringing the total funding to date to $83 million (€70M).

The whole team at TreeFrog Therapeutics wishes you a Happy New Year !